OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Brief Description
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
Trial Physician / Study Coordinator
Kien Nguyen
EmailSponsor
Omeros Corporation
Study Drug
OMS721
Estimated enrollment
430
Estimated end date
April 2023
OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Brief Description
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
Trial is for people with
IgA Nephropathy
Study Goal
To determine if OMS721 reduces proteinuria in patients with IgAN.
What is involved for the Patient?
Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.
About the drug or intervention
MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system.